BioPharm Insight Releases CRO Report on Clinical Trial Activity in 3rd Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Jefferies Cuts Price Target on Parexel (PRXL) to $67 Following Weak 1Q
October 27, 2016 9:33 AM EDTJefferies maintained a Hold rating on PAREXEL International (NASDAQ: PRXL), and cut the price target to $67.00 (from $72.50), following the company's 1Q earnings report. EPS fell 10c below consensus and guidance midpoint. PRXL's revenue shortfall accounted for ~4c. Updated guidance reduces revenue by... More
